

Transthyretin Amyloidosis (ATTR) Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/TBFB9988F1C2EN.html>

Date: March 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: TBFB9988F1C2EN

Abstracts

Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).

This report contains market size and forecasts of Transthyretin Amyloidosis (ATTR) in Global, including the following market information:

Global Transthyretin Amyloidosis (ATTR) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Transthyretin Amyloidosis (ATTR) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Hereditary ATTR (HATTR) Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Transthyretin Amyloidosis (ATTR) include Pfizer,

Amylam Pharmaceuticals, Ionis Pharmaceuticals, Corino Therapeutics, Proclara Bioscience and Arcturus Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Transthyretin Amyloidosis (ATTR) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Transthyretin Amyloidosis (ATTR) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, by Type, 2021 (%)

Hereditary ATTR (HATTR)

Wild-Type (WT) ATTR

Global Transthyretin Amyloidosis (ATTR) Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, by Application, 2021 (%)

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Global Transthyretin Amyloidosis (ATTR) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, By Region and

Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Transthyretin Amyloidosis (ATTR) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Transthyretin Amyloidosis (ATTR) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Alnylam Pharmaceuticals

Ionis Pharmaceuticals

Corino Therapeutics

Proclara Bioscience

Arcturus Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Transthyretin Amyloidosis (ATTR) Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Transthyretin Amyloidosis (ATTR) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL TRANSTHYRETIN AMYLOIDOSIS (ATTR) OVERALL MARKET SIZE

- 2.1 Global Transthyretin Amyloidosis (ATTR) Market Size: 2021 VS 2028
- 2.2 Global Transthyretin Amyloidosis (ATTR) Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Transthyretin Amyloidosis (ATTR) Players in Global Market
- 3.2 Top Global Transthyretin Amyloidosis (ATTR) Companies Ranked by Revenue
- 3.3 Global Transthyretin Amyloidosis (ATTR) Revenue by Companies
- 3.4 Top 3 and Top 5 Transthyretin Amyloidosis (ATTR) Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Transthyretin Amyloidosis (ATTR) Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Players in Global Market
 - 3.6.1 List of Global Tier 1 Transthyretin Amyloidosis (ATTR) Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Transthyretin Amyloidosis (ATTR) Market Size Markets, 2021 & 2028

4.1.2 Hereditary ATTR (HATTR)

4.1.3 Wild-Type (WT) ATTR

4.2 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts

4.2.1 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022

4.2.2 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028

4.2.3 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Transthyretin Amyloidosis (ATTR) Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Ambulatory Surgical Centers

5.1.4 Diagnostic Centers

5.2 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts

5.2.1 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022

5.2.2 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028

5.2.3 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Transthyretin Amyloidosis (ATTR) Market Size, 2021 & 2028

6.2 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts

6.2.1 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022

6.2.2 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028

6.2.3 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028

6.3.2 US Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.3.3 Canada Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.3.4 Mexico Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028

6.4.2 Germany Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.4.3 France Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.4.4 U.K. Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.4.5 Italy Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.4.6 Russia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.4.7 Nordic Countries Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.4.8 Benelux Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028

6.5.2 China Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.5.3 Japan Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.5.4 South Korea Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.5.5 Southeast Asia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.5.6 India Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028

6.6.2 Brazil Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.6.3 Argentina Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028

6.7.2 Turkey Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.7.3 Israel Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.7.4 Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

6.7.5 UAE Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Major Product Offerings

7.1.4 Pfizer Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)

7.1.5 Pfizer Key News

7.2 Alnylam Pharmaceuticals

- 7.2.1 Alnylam Pharmaceuticals Corporate Summary
- 7.2.2 Alnylam Pharmaceuticals Business Overview
- 7.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Major Product Offerings
- 7.2.4 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
- 7.2.5 Alnylam Pharmaceuticals Key News
- 7.3 Ionis Pharmaceuticals
 - 7.3.1 Ionis Pharmaceuticals Corporate Summary
 - 7.3.2 Ionis Pharmaceuticals Business Overview
 - 7.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Major Product Offerings
 - 7.3.4 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
 - 7.3.5 Ionis Pharmaceuticals Key News
- 7.4 Corino Therapeutics
 - 7.4.1 Corino Therapeutics Corporate Summary
 - 7.4.2 Corino Therapeutics Business Overview
 - 7.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Major Product Offerings
 - 7.4.4 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
 - 7.4.5 Corino Therapeutics Key News
- 7.5 Proclara Bioscience
 - 7.5.1 Proclara Bioscience Corporate Summary
 - 7.5.2 Proclara Bioscience Business Overview
 - 7.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Major Product Offerings
 - 7.5.4 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
 - 7.5.5 Proclara Bioscience Key News
- 7.6 Arcturus Therapeutics
 - 7.6.1 Arcturus Therapeutics Corporate Summary
 - 7.6.2 Arcturus Therapeutics Business Overview
 - 7.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Major Product Offerings
 - 7.6.4 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
 - 7.6.5 Arcturus Therapeutics Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Transthyretin Amyloidosis (ATTR) Market Opportunities & Trends in Global Market

Table 2. Transthyretin Amyloidosis (ATTR) Market Drivers in Global Market

Table 3. Transthyretin Amyloidosis (ATTR) Market Restraints in Global Market

Table 4. Key Players of Transthyretin Amyloidosis (ATTR) in Global Market

Table 5. Top Transthyretin Amyloidosis (ATTR) Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Transthyretin Amyloidosis (ATTR) Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Companies, 2017-2022

Table 8. Global Companies Transthyretin Amyloidosis (ATTR) Product Type

Table 9. List of Global Tier 1 Transthyretin Amyloidosis (ATTR) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Transthyretin Amyloidosis (ATTR) Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Transthyretin Amyloidosis (ATTR) Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Transthyretin Amyloidosis (ATTR) Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Transthyretin Amyloidosis (ATTR) Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer Corporate Summary

Table 31. Pfizer Transthyretin Amyloidosis (ATTR) Product Offerings

Table 32. Pfizer Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn), (2017-2022)

Table 33. Alnylam Pharmaceuticals Corporate Summary

Table 34. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product Offerings

Table 35. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn), (2017-2022)

Table 36. Ionis Pharmaceuticals Corporate Summary

Table 37. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product Offerings

Table 38. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn), (2017-2022)

Table 39. Corino Therapeutics Corporate Summary

Table 40. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Product Offerings

Table 41. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn), (2017-2022)

Table 42. Proclara Bioscience Corporate Summary

Table 43. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Product Offerings

Table 44. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn), (2017-2022)

Table 45. Arcturus Therapeutics Corporate Summary

Table 46. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Product Offerings

Table 47. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US\$, Mn),
(2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Transthyretin Amyloidosis (ATTR) Segment by Type in 2021
- Figure 2. Transthyretin Amyloidosis (ATTR) Segment by Application in 2021
- Figure 3. Global Transthyretin Amyloidosis (ATTR) Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Transthyretin Amyloidosis (ATTR) Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Transthyretin Amyloidosis (ATTR) Revenue in 2021
- Figure 8. By Type - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
- Figure 12. US Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
- Figure 16. Germany Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
- Figure 24. China Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn),

2017-2028

Figure 27. Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 28. India Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028

Figure 30. Brazil Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028

Figure 33. Turkey Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Transthyretin Amyloidosis (ATTR) Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Transthyretin Amyloidosis (ATTR) Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/TBFB9988F1C2EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TBFB9988F1C2EN.html>